Healthcare Industry News: OrbusNeich
News Release - May 7, 2013
OrbusNeich enforces injunction against Boston Scientific in GermanyWIESBADEN, Germany, May 7, 2013 -- (Healthcare Sales & Marketing Network) -- OrbusNeich Medical, Inc. and its German subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") announced that it has fulfilled all the requirements established by the Dusseldorf Regional Court, including posting of a performance bond and service to Counsel for the Defendants, and is today enforcing the Preliminary Injunction issued by the Court on April 30, 2013, against Boston Scientific Corporation and its German subsidiary Boston Scientific Medizintechnik GmbH (collectively "Boston Scientific").
The Preliminary Injunction prohibits the importation, distribution, sales and marketing of certain products by Boston Scientific or any other subsidiary of Boston Scientific in or into Germany. Included in the prohibited products are the Boston Scientific cardiac stents sold under the names of PROMUS Element™, PROMUS Element Plus™, OMEGA™, TAXUS Element™, SYNERGY™ and Promus PREMIER™, each in the Small Vessel, Small Workhorse and Workhorse diameter ranges. Boston Scientific would also breach the injunction if they cause other affiliated companies to sell the products in Germany. The Preliminary Injunction provides for significant economic penalties for violation of its terms and restrictions.
Boston Scientific has appealed the Preliminary Injunction. However, until the appeal is decided, which OrbusNeich expects will be in 6 to 9 months, the Injunction remains in force. OrbusNeich believes that the injunctive relief is justified and will defend the appeal along with vigorously prosecuting its patent infringement claims in the principal case filed in the Dusseldorf Court. OrbusNeich has stated that it expects the principle patent infringement case to be heard in May 2014.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.
Source: OrbusNeich Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.